.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Minor ischemic stroke can be deceptive: a low NIHSS score does not always mean a low risk of disability, particularly when a visible intracranial occlusion is present. TEMPO-2 was a randomized phase 3 trial testing whether tenecteplase was superior to standard care in patients with minor ischemic stroke and proven occlusion or focal perfusion abnormality. The study did not demonstrate the expected clinical benefit from tenecteplase in this population and raised safety concerns. The result is important because it cautions against automatically extrapolating the benefits of thrombolysis established in more typical acute ischemic stroke populations to patients with minor deficits. For HCPs, the practical lesson is that treatment decisions should incorporate both neurological severity and vascular/imaging findings, but an apparent mismatch does not automatically justify thrombolysis. Patients with minor stroke may still require careful observation and secondary prevention because early deterioration remains possible. The trial is highly relevant to IANCON's discussion of grey zones in thrombolysis and reinforces the need for evidence specific to challenging stroke phenotypes.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Minor ischemic stroke can be deceptive: a low NIHSS score does not always mean a low risk of disability, particularly when a visible intracranial occlusion is present. TEMPO-2 was a randomized phase 3 trial testing whether tenecteplase was superior to standard care in patients with minor ischemic stroke and proven occlusion or focal perfusion abnormality. The study did not demonstrate the expected clinical benefit from tenecteplase in this population and raised safety concerns. The result is important because it cautions against automatically extrapolating the benefits of thrombolysis established in more typical acute ischemic stroke populations to patients with minor deficits. For HCPs, the practical lesson is that treatment decisions should incorporate both neurological severity and vascular/imaging findings, but an apparent mismatch does not automatically justify thrombolysis. Patients with minor stroke may still require careful observation and secondary prevention because early deterioration remains possible. The trial is highly relevant to IANCON's discussion of grey zones in thrombolysis and reinforces the need for evidence specific to challenging stroke phenotypes.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
